阿尔茨海默病中的多交叉随机对照试验设计
本文指出传统平行组随机对照试验在阿尔茨海默病中样本量大、耗时长、费用高且对临床变化不敏感。多交叉安慰剂对照双盲随机对照试验(包括单例N-of-1设计)让受试者自身对照,可控制异质性,并通过个性化结局提高敏感性和特异性。作者认为多交叉设计在AD中具有诸多优势,但几乎从未被实施。
要点
- 多交叉随机对照试验让受试者自身对照,可控制人口学、遗传、症状等异质性。
- 纳入个性化结局指标可进一步提高敏感性和特异性。
- 多例N-of-1试验联合分析可在更小样本中估计群体疗效。
核心结论
- 作者认为在阿尔茨海默病中,对于作用机制、药代动力学和药效学合适的药物或其他治疗,多交叉随机对照试验较标准平行组试验具有诸多优势,尽管其几乎从未被实施。
- 多交叉N-of-1随机对照试验可无偏估计单例疗效,多例N-of-1试验联合分析可在比传统平行组研究所需样本量小得多的情况下估计群体疗效。
- 多交叉设计可能尤其适用于针对认知和神经精神症状症状性改善的疗法,也可用于采用生物标志物结局指标的疾病修饰治疗的早期研究。
研究设计与样本
- 本文为方法学论述,讨论在阿尔茨海默病中开展多交叉、安慰剂对照、双盲随机对照试验(包括样本量小至单例的N-of-1设计)的设计。
- 受试者在重复的随机序列交叉治疗区组中作为自身对照。
- 需识别携带效应和自然病史时间趋势,以实现治疗效应的无偏估计和检验。
主要发现
- 传统平行组随机对照试验在阿尔茨海默病中必须采用非常大的样本和宽泛的变化测量,以容纳人口学、遗传学、症状、病理生理、合并症和进展速度的显著异质性。
- 多交叉设计固有地控制异质性,纳入每个个体的个性化结局指标可进一步提高结局的敏感性、特异性和临床相关性。
- 多交叉N-of-1随机对照试验可无偏估计单例疗效,多例N-of-1试验联合分析可在比传统平行组研究所需样本量小得多的情况下估计群体疗效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Conventional parallel group randomized controlled clinical trials (RCT) in Alzheimer’s disease (AD) are too large, long, expensive and insensitive to clinical change to meet the urgent need for an effective treatment. While providing good evidence for a treatment’s benefit, parallel group RCTs in AD must have very large samples and broad measures of change to accommodate the marked heterogeneity of demographics, genetics, symptoms, pathophysiologies, comorbidities and rates of progression. Multi-crossover, placebo-controlled, double-blind RCTs, including those with sample sizes as small as a single subject (“N-of-1”), are robust designs wherein subjects serve as their own controls in repeated blocks of randomly sequenced crossover treatments. Heterogeneities are inherently controlled and the sensitivity, specificity and clinical relevance of outcomes can be enhanced further by including personalized outcome measures for each individual. Multi-crossover N-of-1 RCTs enable unbiased estimation of efficacy for single subjects, and joint analysis of multiple N-of-1 trials enables estimation of efficacy for populations with much smaller sample sizes than those needed in conventional parallel group studies. It is important to identify carryover effects and natural history time trends to achieve unbiased estimation and testing of the treatment effect. We assert that in AD, multi-crossover RCTs offer many advantages over standard parallel group trials for drugs or other treatments with suitable mechanisms of action, pharmacokinetics and pharmacodynamics; despite the fact that they are almost never conducted. They may be especially useful for therapies directed at symptomatic improvement of cognitive and neuropsychiatric symptoms, but also can be used in early phase studies of disease modifying treatments with biomarker outcome measures.
引用
- Arnold SE, Betensky RA. Multicrossover Randomized Controlled Trial Designs in Alzheimer Disease. Ann Neurol. 2018. PMID: 30014506. doi:10.1002/ana.25280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。